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S U M M A R Y
Background: The increasing emergence of clinical infections caused by methicillin-resistant
Staphylococcus aureus (MRSA) challenges existing therapeutic options and highlights the need to
develop novel treatment strategies. The ftsZ gene is essential to bacterial cell division.
Methods: In this study, two antisense peptide nucleic acids (PNAs) conjugated to a cell-penetrating
peptide were used to inhibit the growth of MRSA. PPNA1, identiﬁed with computational prediction and
dot-blot hybridization, is complementary to nucleotides 309–323 of the ftsZ mRNA. PPNA2 was designed
to target the region that includes the translation initiation site and the ribosomal-binding site (Shine–
Dalgarno sequence) of the ftsZ gene. Scrambled PPNA was constructed with mismatches to three bases
within the antisense PPNA1 sequence.
Results: PPNA1 and PPNA2 caused concentration-dependent growth inhibition and had bactericidal
effects. The minimal bactericidal concentrations of antisense PPNA1 and PPNA2 were 30 mmol/l and
40 mmol/l, respectively. The scrambled PPNA had no effect on bacterial growth, even at higher
concentrations, conﬁrming the sequence speciﬁcity of the probes. RT-PCR showed that the antisense
PPNAs suppressed ftsZ mRNA expression in a dose-dependent manner.
Conclusion: Our results demonstrate that the potent effects of PNAs on bacterial growth and cell viability
were mediated by the down-regulation or even knock-out of ftsZ gene expression. This highlights the
utility of ftsZ as a promising target for the development of new antisense antibacterial agents to treat
MRSA infections.
 2014 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/3.0/).
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Methicillin-resistant Staphylococcus aureus (MRSA), a horriﬁc
superbug, has become an overwhelming pathogenic threat to
human health.1 The high rate of MRSA infection is a great burden
to the clinical treatment and control of nosocomial infections.
Currently, linezolid and vancomycin are used as the ﬁrst-line drugs
for the treatment of serious MRSA infections. However, several
linezolid-resistant strains have been reported.2 Patients with
MRSA bloodstream infections and high minimum inhibitory
concentrations (MICs) for vancomycin have a greater likelihood
of treatment failure and mortality.3 The strong resistance of MRSA* Corresponding author. Tel.: +86 023 89012742; fax: +86 023 89012513.
E-mail address: xiayun12cn@aliyun.com (Y. Xia).
http://dx.doi.org/10.1016/j.ijid.2014.09.015
1201-9712/ 2014 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).to antibiotics makes clinical treatment difﬁcult and has created
an urgent demand for the discovery and development of new
antibacterial agents directed toward novel targets to avoid
cross-resistance to licensed antibiotics.
The processes of bacterial cell division are promising targets for
new antibacterial drugs.4–7 ftsZ is the most conserved of all known
bacterial cell-division genes and encodes the bacterial proto-ring
protein FtsZ, and so plays a key role in bacterial cell division. It is
the ﬁrst protein to localize at the site of incipient division and
functions as a GTP-dependent guanosine triphosphatase, like the
tubulin protein in eukaryotic cells. It recruits the other cell-division
proteins in an orderly way to form the Z ring, which leads the
constriction of the cell membrane, and coordinates the whole
process of cell division. Because it has a pivotal role in initiating
the whole process of cell division, FtsZ is an attractive target forciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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inhibitors of FtsZ have been suggested for the treatment of
antibiotic-resistant bacterial infections, such as S. aureus and
Escherichia coli.8–11
Exploiting the antisense mechanism is a way to silence the
expression of a target gene at the mRNA level in a sequence-
speciﬁc manner. Antisense antibacterial agents are short (about
10–20 bases). Peptide nucleic acids (PNAs), locked nucleic acids
(LNAs), and phosphorodiamidate morpholino oligomers (PMOs)12,13
are synthetic nucleic acid analogues that inhibit targeted gene
expression at the level of DNA replication or transcription.14,15 PNAs,
which lack a negative charge and are quite stable against nucleases,
exert potent antisense effects, while they are not susceptible to
active efﬂux from the cell. These features make them attractive
candidates as antisense antimicrobial agents. However, a major
hurdle in the development of PNAs as antimicrobials is the
inefﬁcient delivery of PNAs to cells.16 Numerous studies have
demonstrated that conjugating a cell-penetrating peptide (CPP) to a
PNA dramatically improves its antisense activity.17 Currently, the
peptide (RXR)4XB is most commonly used in prokaryotic organisms
to enhance the entry of PNAs.
In this study, antisense oligonucleotides targeting the ftsZ
gene were designed and peptide-conjugated PNAs (PPNAs) were
synthesized to evaluate their inhibitory effects on MRSA growth in
vitro.
2. Materials and methods
2.1. Bacterial strains and culture conditions
The MRSA strain CY-11 was isolated from a clinical sample,
identiﬁed with the VITEK 2 Compact System (bioMe´rieux, Lyon,
France), and conﬁrmed to be mecA gene-positive with PCR. The
mecA gene was ampliﬁed by PCR with the forward primer
50-GGTACTGCTATCCACCCTCAAA-30 and the reverse primer 50-
TTACGACTTGTTGCATACCATCA-30.18 The PCR product was se-
quenced and compared to known mecA gene sequences in
GenBank. Antibiotic sensitivity tests showed that this strain is
resistant to oxacillin (MIC 4 mg/l), benzylpenicillin (MIC 0.5 mg/
l), erythromycin (MIC 8 mg/l), gentamicin (MIC 16 mg/l),
ciproﬂoxacin (MIC 8 mg/l), clindamycin (MIC 8 mg/l), levoﬂox-
acin (MIC 8 mg/l), tetracycline (MIC 16 mg/l), and moxiﬂoxacin
(MIC 8 mg/l), according to the standards of the Clinical and
Laboratory Standards Institute (CLSI, USA, 2013).Table 1
Probe sequence for screening the effective antisense oligonucleotides
Probe sequence (50–30) Target sitea Paramet
Overall
DG
GTGGTCAATCATTCGGTTTA 80–99 18.3 
CGTGTTAATTTTTCACCGAT 181–200 12 
CCGCCACCCATACCAGAAGT 304–323 16.6 
CACCAACAGTTAATGCGCCC 372–391 10.6 
TGTCAACGATATCTAATAAA 504–523 11 
TGTACACCTTGGCGTAACAC 565–584 10.3 
TGAGATACCTTGTACACCTT 575–594 15.4 
TTCTACCGCTCTATTTTCAC 698–717 15.2 
ATGACTCGCCACCAGTAATA 789–808 13.9 
TAGTTGTATGCGTTCTTTCA 1086–1105 12.2 
GCTGCAGAGGAATCTCGTGA Control sequence ND 
ND, not determined.
a Numbering from the ﬁrst base of the gene ftsZ.
b DG means free energy. Index for each parameter: overall DG <10 kcal/mol; duple
Tm >50 8C.2.2. Screening the effective antisense oligomers
2.2.1. Full-length ftsZ gene cloning and in vitro transcription
The genomic DNA of MRSA CY-11 was extracted with a
TIANamp Bacteria DNA Kit, based on afﬁnity columns (Tiangen,
Beijing, China), according to the manufacturer’s protocol. The full-
length ftsZ gene (GenBank accession number NC_002952)
was ampliﬁed by PCR with the forward primer 50-CCAATAAAAC-
TAGGAGGAAA-30 and the reverse primer 50-ACCGATTAACGTCTTG-
TTCTTCTT-30. The PCR product was sequenced and cloned into the
pGEM-T Easy vector (Promega, Fitchburg, WI, USA), generating the
recombinant plasmid designated GEM-T–ftsZ. In the recombinant
plasmid, the full-length ftsZ gene was correctly inserted down-
stream from the T7 promoter, and the recombinants were selected
and linearized with SpeI (Promega). ftsZ mRNA was transcribed in
vitro with Riboprobe Systems-T7 (Promega) in the presence of
digoxigenin–recombinant 11-uridine-50-triphosphate (DIG–rUTP;
Roche), according to the manufacturer’s instructions. Brieﬂy, a
20-ml reaction was set up containing 4 ml of Transcription
Optimized 5 Buffer, 2 ml of 100 mM DL-Dithiothreitol (DTT),
0.5 ml of Recombinant RNasin Ribonuclease Inhibitor, rATP, rGTP,
rATP, and rUTP (2.5 mM each), 3.75 mg of linearized template DNA,
and 1 ml of T7 RNA polymerase. Nuclease-free water was added to
a ﬁnal volume of 20 ml. After incubation at 37 8C for 3 h, the DNA
was removed by digestion with DNaseI for 30 min. To prepare the
RNA transcripts for dot-blot hybridization (described below), UTP
and DIG–UTP were added to the transcription reaction in a ratio of
13:7. The RNA transcripts were puriﬁed, quantiﬁed, and stored as
aliquots in nuclease-free water at 80 8C until analysis.
2.2.2. Antisense oligonucleotide probe design, computational
screening with prediction software, and dot-blot hybridization
The secondary structure of the ftsZ mRNA was predicted with
Mfold software and the RNA structure 5.5 program, based on
minimal free energy theory. In total, 10 plausible target sites
lacking obvious stable secondary structures, such as stem-loops
or hairpins, were selected as antisense oligonucleotide probes.
One oligonucleotide from the sense strand sequence was used
as the negative control. The sequences of the antisense oligonu-
cleotide probes and their parameters are listed in Table 1. These
11 oligonucleotides were hybridized to the ftsZ transcription
product with dot-blot hybridization (DIG Luminescent Detection
Kit, Roche), according to the manufacturer’s instructions, to
evaluate their binding activity to the ftsZ mRNA.ersb
Oligo–self DG Oligo–oligo
DG
Tm (8C)
0 3.9 67.9
0 3.8 62.1
0 2.4 76.3
0 7 70.4
0 5.6 50.2
0 5.8 68.5
0 6 67.4
0 2.8 68.9
0 2.6 67.8
0 3.4 68.4
ND ND ND
x DG <25 kcal/mol; oligo–self DG 1.1 kcal/mol; oligo–oligo DG 8 kcal/mol;
Figure 1. Result of dot blot hybridization of the designed antisense oligonucleotide
probes with the ftsZ mRNA transcribed in vitro. 1–11: antisense oligonucleotide
probes; P: positive control.
Table 2
Antisense PNAs used to investigate MRSA gene expression and growth
PNA designationa Sequenceb Target sitec
PPNA1 50-(RXR)4XB-eg1-CCGCCACCCATACCA -30 (309, 323)
PPNA2 50-(RXR)4XB-eg
1-CATTTAAATTTC-30 (9, +3)
ScrPPNA1 50-(RXR)4XB-eg
1-CGGACACCCATAACA-30
MRSA, methicillin-resistant Staphylococcus aureus.
a PNA, peptide nucleic acid; PPNA peptide-conjugated PNA.
b The PNAs are given from their N- to C-termini; the N-terminus corresponds to
the 50 end of a conventional oligonucleotide. ‘X’ indicates 6-aminohexanoic acid, ‘B’
1
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PNAs conjugated with CPP were synthesized with manual
coupling chemistry and puriﬁed by Panagene Inc. (Daeheon,
Korea). All the PNAs used were covalently conjugated with the CPP
(RXR)4XB (in which R is arginine, X is 6-aminocaproic acid, and B is
b-alanine) at the carbonyl terminus (corresponding to the 30 end
of a conventional oligonucleotide). All the PNAs were diluted to
250 mmol/l with ddH2O and stored at 20 8C until analysis.
2.4. Inhibition of bacterial growth
MRSA strain CY-11 was grown overnight in 5 ml of
Mueller–Hinton (MH) broth at 37 8C with continuous orbital
shaking at 225 rpm. A fresh overnight culture was diluted with MH
broth to approximately 105 cells per 200 ml in each well of a 96-
well plate. Various antisense PPNAs or the scrambled peptide–PNA
were added to the wells, at ﬁnal concentrations of 0, 10, 20, 30, and
40 mmol/l. The microtiter plates were incubated at 37 8C, and the
optical density at 600 nm (OD600) was measured with a Sunrise
microplate reader (Tecan, Zurich, Switzerland) every hour to
evaluate the growth rates of MRSA. Samples were taken at different
time points (0, 2, 4, 6, and 8 h) during culture, plated onto MH agar
at the appropriate dilutions, and grown overnight at 37 8C. Theindicates b-alanine, and eg indicates glycine.
c Numbering from the ﬁrst base of the gene ftsZ.
Figure 2. Effect of peptide-conjugated PNA (PPNAs) on growth of MRSA CY11. Peptide nucleic acid (PNA) nucleobases are shown in lowercase letters and peptide in uppercase
letters. MRSA CY11 growth is indicated by OD600. Concentration-dependent growth inhibition of MRSA CY11 by PPNA1 (A) and PPNA2 (B). No growth inhibition of MRSA
CY11was observed with ScrPPNA1 (C). R is arginine, X is 6-aminocaproic acid, and B is b-alanine.
Figure 3. Concentration- and time-dependent bacteriocidal antisense effects of
anti- ftsZ against MRSA CY-11. Cultures were established in Mueller–Hinton broth
at 105 CFU/ml and treated with anti-ftsZ PPNA1 (A) or PPNA2 (B) at different
concentrations. The number of colony-forming units was determined at different
time points on Mueller–Hinton agar.
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inhibitory effects of the different PPNAs.
2.5. Evaluating the inhibitory effect on ftsZ gene expression with
RT-PCR
To detect the expression of the ftsZ gene in MRSA, total RNA
was extracted from 18-h cultures that had been treated with
different concentrations of various antisense CPP–PNA oligomers
or controls. RT-PCR analysis of the ftsZ gene (F: 50-AAAGCTGCA-
GAGGAATCTCG-30 and R: 50-TTTAGCAACGACTGGTGCTG-30)19 was
performed with the RNeasy Mini Kit (Tiangen Biotech, Beijing,
China), and 16S rRNA was used as the internal control (F: 50-
AGTTTGATC(A/C)TGGCTCAG-30 and R: 50-GGACTAC(C/T/A)AGGG-
TATCTAAT-30).20 The reactions were performed in the LightCycler
PCR System under the following conditions: 30 cycles of
denaturation (30 s at 94 8C), annealing (30 s at 58 8C), and
extension (1 min at 72 8C), with a ﬁnal extension at 72 8C for
10 min. The ampliﬁed fragments were analyzed by electrophoresis
on a 1% agarose gel.
3. Results
3.1. Selection of an effective antisense oligonucleotide
The secondary structure of the ftsZ mRNA was predicted
by computer software in sequence lengths of 20 bases. Tenoligonucleotides complementary to these sites and one oligonu-
cleotide from the sense-strand sequence were synthesized as
probes. The binding activity of these oligonucleotides to the ftsZ
mRNA was evaluated with dot-blot hybridization. As shown in
Figure 1, only six oligonucleotides exhibited different levels of
hybridization signals on the dot blot. Of these, the number 3 probe
showed the strongest hybridization signal, whereas the negative
control (with a sense sequence) showed no hybridized signal.
These results indicate that most of the antisense oligonucleotides
did not access the mRNA target because the mRNA secondary
structural conformation precluded this access. The antisense
oligonucleotides were rapidly and reliably screened with this
combination of computer software and dot-blot hybridization.
The PNA oligomer was synthesized based on the sequence of
probe 3 and conjugated with a considerably more effective
peptide (RXR)4XB
21. This conjugation provides a broader anti-
bacterial spectrum and more potent bactericidal effects than
traditional (KFF)3K-conjugated PNAs.
22 PPNA2, which targeted
the region including the translation initiation site and the
ribosomal-binding site, was synthesized to compare its effective-
ness with that of PPNA1 because several studies have indicated
that these areas offer the most sensitive targets for antisense
inhibition in bacteria.22 Scrambled PPNA1, in which three bases
of antisense PPNA1 were substituted, was used as the control
(Table 2).
3.2. Inhibiting the growth of MRSA with PPNAs targeting ftsZ
The growth of MRSA strain CY-11 was evaluated to examine
the inhibitory effects of various concentrations of antisense
PPNA1, PPNA2, or scrambled PPNA1. PPNA1 and PPNA2 inhibited
MRSA growth in a concentration-dependent manner. The growth
of MRSA was entirely inhibited by PPNA1 at a concentration
of 30 mmol/l (Figure 2A) and by PPNA2 at a concentration of
40 mmol/l (Figure 2B). No growth inhibition was observed in
cultures treated with scrambled PPNA1, even at a concentration of
40 mmol/l (Figure 2C).
The bactericidal effects of the anti-ftsZ PPNAs were evaluated
with cell viability assays. The number of MRSA CFU decreased
markedly from a starting value of 105 CFU/ml to 102 CFU/ml in 2 h
and no viable cells were detected 6 h after treatment with PPNA1
at a concentration of 40 mmol/l (Figure 3A). PPNA2 had no
obvious bactericidal effects, even at a concentration of 40 mmol/l
(Figure 3B). The results of the cell viability assays and the cell
growth inhibition assays described above demonstrate that
PPNA1 exerts a potent antibacterial effect in vitro. The
sequence screened with computational analysis and dot-blot
hybridization had more effective antisense activity than the
sequence targeted to the region that included the translation
initiation site and the ribosomal-binding site (Shine–Dalgarno
sequence).23
3.3. Inhibiting ftsZ gene expression
To examine the possibility that the reduction in viable bacterial
cells described above was caused by the decay of the ftsZ mRNA
transcripts after treatment with antisense PPNA, the expression of
ftsZ mRNA was assayed with RT-PCR (Figure 4). The levels of ftsZ
mRNA decreased in a dose-dependent manner when treated
with PPNA1 or PPNA2. PPNA1 treatment eliminated ftsZ mRNA
expression, whereas ftsZ mRNA expression was almost unchanged
when treated with scrambled PPNA1 at the same concentration
(40 mmol/l). These results demonstrate that the antisense gene
knock-down effect was sequence-speciﬁc.
Figure 4. Speciﬁc inhibition of MRSA CY-11 ftsZ mRNA expression by PPNA in a concentration-dependent manner. Bacterial cultures treated with different concentrations of
various anti-ftsZ PPNAs or control were grown at 37 8C for 18 h in Mueller–Hinton broth and total RNA was extracted. The levels of ftsZ mRNA were determined by RT-PCR. 16S
rRNA was used as the internal control.
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MRSA, as a frightening ‘superbug’, is one of the most common
pathogens causing clinical infection. Currently, the spread of MRSA
has limited the therapeutic options available and requires new
approaches to targeted drug discovery. Antisense antibacterial
strategies have been shown to effectively inhibit bacterial gene
expression and cell growth, making this technique attractive for
developing highly speciﬁc and efﬁcacious antibacterial agents.24,25
However, the antisense effect is less pronounced for Gram-positive
species than for Gram-negative species and only a few early
reports have provided preliminary proof-of-principle evidence
that the antisense targeting of S. aureus genes has a growth-
inhibitory effect.26,27
Cell division is essential in the bacterial life cycle. To date, no
cell-division protein is the target of a licensed antibiotic. The ftsZ
gene is an attractive target for new antibacterial drugs because it
plays an important role in bacterial cell division. FtsZ inhibitors
signiﬁcantly inhibit the growth of MRSA,8 and because they do not
cross-react with human tubulin, FtsZ inhibitors should not be toxic
to human cells. A previous study found that inhibiting the FtsZ
protein with berberine9 or inhibiting ftsZ gene expression using
external guide sequences inhibited the growth of E. coli in vitro.28
Therefore, inhibiting the ftsZ gene with antisense agents is a
promising strategy for the development of novel antimicrobial
agents for Gram-positive cocci, including MRSA.
After identifying genes that are essential for bacterial growth
and are susceptible to antisense inhibition, the most challenging
aspect of designing complementary antisense oligodeoxynucleo-
tides is the selection of antisense sequences that will exert potent
and speciﬁc inhibitory effects. Generally, computer software is
used to predict the secondary structure of the target mRNA29,30 and
the antisense sequence is designed accordingly. In our previous
study, we screened a potential antisense oligonucleotide targeting
the motA transcripts of Pseudomonas aeruginosa strain PAO1 using
computational prediction and dot-blot hybridization. The oligo-
nucleotide displayed effective inhibitory activity against bioﬁlm
formation by PAO1 at a concentration of 10 mmol/l.31 Some
researchers have reported that the translation initiation site and
the ribosomal-binding site are sensitive to antisense inhibition and
can be used as the sequences of antisense probes. Our results show
that the PNA designed to the screened antisense sequence exerted
a better inhibition and a more robust bactericidal effect than the
PNA targeted to the translation initiation site and ribosomal-
binding site (effective concentrations of 30 mmol/l vs. 40 mmol/l,
respectively). Therefore, the full length of a target gene should be
screened for effective antisense sequences.
In several studies, CPP-conjugated PNAs have been tested in
Gram-positive bacteria. In general, the antisense effect was less
pronounced in Gram-positive species than in E. coli and a higher
PNA concentration was required to reduce growth.32 Growth
inhibition by anti-gyrA peptide PNAs has been reported at a higher
concentration in S. aureus (>10 mmol/l)27 than in Acinetobacter
baumannii (5 mmol/l).33 Growth inhibition by (RXR)4XB-coupled
antisense PNAs speciﬁc to rpoD, encoding for RNA polymeraseprimary sigma factor s70, was achieved in MRSA at a PNA
concentration of 40 mmol/l.34 In this study, we identiﬁed an
antisense sequence displaying growth inhibition at a concentra-
tion <30 mmol/l and bactericidal effects at a concentration of
40 mmol/l. The slightly higher concentration required to inhibit
MRSA growth may be attributable to the existence of multiple
copies of the ftsZ gene in bacterial cells.
To explore the antisense mechanism further, the effects of PPNA
on ftsZ transcripts in MRSA were evaluated with RT-PCR. The dose-
dependent down-regulation of ftsZ gene expression in MRSA was
observed, and no expression was detectable when antisense
PPNA1 was used at a concentration of 40 mmol/l. These results
indicate that the potency of the PNA on bacterial growth and cell
vitality is mediated by the down-regulation or even knock-out of
ftsZ expression.
In this study, we report the ﬁrst application of an antisense
PNA targeting the ftsZ gene to inhibit MRSA growth in vitro. The
results of this study provide new insight into the application
of antisense PNAs to the treatment of antibiotic-resistant
staphylococcal infections. Further research is required to evaluate
the potency, safety, and pharmacokinetics of PPNAs for use in the
clinical treatment of MRSA infections.
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